诺和诺德全球首创新药在华获批;罗氏公布amylin减重临床数据

药创新
Mar 08

“药创新”综合整理过去一周,创新药行业发生了哪些事儿?诺和诺德全球首创新药在华获批,实现“中国首发”;罗氏53亿美元收购的amylin减重管线公布临床数据;国产自免TCE管线授权给优时比;司美格鲁肽在华递交MASH适应症上市申请;RNAi疗法龙头公司Alnylam加码心血管领域;跨国药企中国区迎来重要高管变动……详情如下:诺和诺德全球首创降糖新药在华获批3月3日,诺和诺德产品诺和杰(依柯胰岛素司...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10